AltheaDx is currently developing unique diagnostic assays, including OncoScore™ Ovarian in a collaborative effort with Compendia Bioscience. The OncoScore™ diagnostic assays are based on the premise that gene expression patterns in cancer are capable of stratifying patients and that this molecular heterogeneity of cancer can be reduced to small number of core gene expression “modules” of biological function which correspond to cell lineage, pathway activation, de-regulation of a cellular process, genomic alterations or tumor microenvironment. For more information on GOG, see: Gynecologic Oncology Group 83rd Semi-Annual Meeting
SAN DIEGO, June 27, 2011 — AltheaDx, Inc. today announced the launch of next-generation sequencing “NGS” services into its clinical molecular pathology lab for application in biomarker discovery and clinical trial testing. AltheaDx intends to utilize NGS for both monitoring known and discovering new complex genetic changes that underlie different cancer types.
Personalized Oncology: The Emergence of Personalized Medicine Strategies in Oncology Clinical Development and Deal Making. Speakers include Dr. Joe Monforte, Ph.D., EVP, CSO, AltheaDx, chaired by John Freshley, CBO Compendia Bioscience
SAN DIEGO — December 8, 2010 — AltheaDx, Inc. today announced the formation of a strategic partnership with Compendia Bioscience to combine their respective core capabilities in assay development, validation and bioinformatics. The two companies will jointly create novel products and services focused on cancer biomarker discovery and subsequent development of tests that predict patient outcomes in clinical trials. From 2006, AltheaDx has enabled FFPE tissue-based biomarker discovery and companion diagnostic development. AltheaDx has facilitated the clinical utilization of biomarkers through validation and clinical sample testing under GLP and/or CLIA.